Multiple Myeloma: all 3,712 studies

Page 9 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.

• COVID-19 VAX Booster Dosing in Patients With Hematologic MalignanciesCompletedNCT05028374Phase 2Results posted
• A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to TreatmentCompletedNCT05014412Phase 2Results posted
• Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple MyelomaCompletedNCT04999085Not applicableResults posted
• Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell TherapyCompletedNCT04975555Phase 2Results posted
• A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Phase 3Results posted
• Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple MyelomaTerminatedNCT04896658Phase 1/2Results posted
• Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT04892446Phase 2Results posted
• A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor TherapyCompletedNCT04847050Phase 2Results posted
• Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma PatientsTerminatedNCT04843579Phase 2Results posted
• GEN3014 Trial in Relapsed or Refractory Hematologic MalignanciesTerminatedNCT04824794Phase 1/2Results posted
• Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyTerminatedNCT04816526Phase 2Results posted
• MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple MyelomaCompletedNCT04798586Phase 1Results posted
• A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)TerminatedNCT04776018Phase 1/2Results posted
• Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma PatientsTerminatedNCT04770402Not applicableResults posted
• Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT04756401Phase 2Results posted
• Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate CancerCompletedNCT04731844Phase 2Results posted
• A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple MyelomaTerminatedNCT04700176Phase 2Results posted
• Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)CompletedNCT04682405Phase 2Results posted
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAbCompletedNCT04649359Phase 2Results posted
• Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple MyelomaTerminatedNCT04649060Phase 3Results posted
• Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple MyelomaTerminatedNCT04635735Phase 1/2Results posted
• To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple MyelomaTerminatedNCT04582539Phase 1/2Results posted
• MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple MyelomaCompletedNCT04552743Phase 2Results posted
• Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab MafodotinTerminatedNCT04549363Phase 3Results posted
• Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT04484623Phase 3Results posted
• Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood CancerCompletedNCT04478123Phase 2Results posted
• Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving ChemotherapyTerminatedNCT04465760Phase 2Results posted
• Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or LymphomaActive, not recruitingNCT04459416Phase 3Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)Active, not recruitingNCT04439357Phase 2Results posted
• Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)Active, not recruitingNCT04439344Phase 2Results posted
• Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)Active, not recruitingNCT04439331Phase 2Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)Active, not recruitingNCT04439318Phase 2Results posted
• Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)Active, not recruitingNCT04439292Phase 2Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)Active, not recruitingNCT04439279Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)Active, not recruitingNCT04439266Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)Active, not recruitingNCT04439253Phase 2Results posted
• Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)CompletedNCT04439240Phase 2Results posted
• Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)Active, not recruitingNCT04439227Phase 2Results posted
• Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)CompletedNCT04439214Phase 2Results posted
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)Active, not recruitingNCT04439188Phase 2Results posted
• Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)Active, not recruitingNCT04439175Phase 2Results posted
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)Active, not recruitingNCT04439149Phase 2Results posted
• Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)Active, not recruitingNCT04439136Phase 2Results posted
• Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)Active, not recruitingNCT04439123Phase 2Results posted
• Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)Active, not recruitingNCT04439110Phase 2Results posted
• Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyCompletedNCT04436029Phase 2Results posted
• A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple MyelomaCompletedNCT04434469Phase 1Results posted
• KRDI in Transplant-Eligible MMActive, not recruitingNCT04430894Phase 2Results posted
• Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With DaratumumabTerminatedNCT04407442Phase 2Results posted
• A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal FunctionActive, not recruitingNCT04398745Phase 1Results posted
• A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to DaratumumabActive, not recruitingNCT04302324Phase 2Results posted
• A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)TerminatedNCT04272775Phase 1Results posted
• Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT04246047Phase 3Results posted
• Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesCompletedNCT04205409Phase 2Results posted
• Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple MyelomaTerminatedNCT04205240Phase 2Results posted
• Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib TripletCompletedNCT04191616Phase 2Results posted
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive, not recruitingNCT04181827Phase 3Results posted
• A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT04177823Phase 1Results posted
• Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT04162210Phase 3Results posted
• Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple MyelomaCompletedNCT04151667Phase 2Results posted
• Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based TherapyActive, not recruitingNCT04140162Phase 2Results posted
• Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT04126200Phase 1/2Results posted
• Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaTerminatedNCT04119336Phase 2Results posted
• Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04113018Phase 2Results posted
• Precision Medicine for Patients With Identified Actionable MutationsTerminatedNCT04111107Phase 2Results posted
• Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple MyelomaTerminatedNCT04097301Phase 1/2Results posted
• Influenza Vaccination for Flu Prevention in Patients With Plasma Cell DisordersCompletedNCT04080531Phase 4Results posted
• First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With DexamethasoneTerminatedNCT04075721Phase 1Results posted
• Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor HealthCompletedNCT04000880Not applicableResults posted
• Descartes-11 in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT03994705Phase 1Results posted
• T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple MyelomaCompletedNCT03958656Phase 1Results posted
• sdAb-based TRNT of Multiple Myeloma: a Feasibility StudyCompletedNCT03956615Not applicableResults posted
• A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Phase 2Results posted
• Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM TrialCompletedNCT03941860Phase 3Results posted
• Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple MyelomaCompletedNCT03934684Phase 4Results posted
• Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple MyelomaTerminatedNCT03910439Phase 2Results posted
• A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell TransplantCompletedNCT03901963Phase 3Results posted
• A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)TerminatedNCT03875495Phase 1/2Results posted
• Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With DaratumumabTerminatedNCT03871829Phase 2Results posted
• Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple MyelomaTerminatedNCT03870451Not applicableResults posted
• A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03859427Phase 3Results posted
• Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT03848845Phase 1/2Results posted
• INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple MyelomaTerminatedNCT03837509Phase 1/2Results posted
• An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma TreatmentsCompletedNCT03828292Phase 1Results posted
• Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple MyelomaTerminatedNCT03782064Phase 2Results posted
• LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaCompletedNCT03773107Phase 1/2Results posted
• Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to TreatmentCompletedNCT03770260Phase 1Results posted
• A Study of Colesevelam for Lenalidomide-Associated DiarrheaCompletedNCT03767257Phase 2Results posted
• Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Phase 3Results posted
• Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple MyelomaCompletedNCT03713294Phase 2Results posted
• Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple MyelomaActive, not recruitingNCT03710603Phase 3Results posted
• Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT03702725Phase 1Results posted
• Tinostamustine Conditioning and Autologous Stem CellTerminatedNCT03687125Phase 1/2Results posted
• First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal AntibodyCompletedNCT03665155Phase 1/2Results posted
• A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial TherapyCompletedNCT03652064Phase 3Results posted
• PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal FunctionTerminatedNCT03639610Phase 2Results posted
• Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)TerminatedNCT03634800Phase 2Results posted
• Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell TransplantTerminatedNCT03622775Phase 2Results posted
• T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple MyelomaCompletedNCT03602612Phase 1Results posted
• A Safety Study of SEA-BCMA in Patients With Multiple MyelomaTerminatedNCT03582033Phase 1Results posted

← Multiple Myeloma overview